743028
Last Update Posted: 2010-10-07
Recruiting has ended
All Genders accepted | 18 Years + |
36 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Assess the Oral Bioavailability of New ABT-263 Formulations
This is a randomized, open-label, multicenter crossover study to determine the oral bioavailability of new ABT-263 formulations relative to that of the current ABT-263 formulation being administered in ongoing Phase 1/2a studies. Approximately 36 evaluable subjects with lymphoid malignancies, including chronic lymphocytic leukemia, and solid tumors will be enrolled in this study.
Eligibility
Relevant conditions:
Chronic Lymphocytic Leukemia
Lymphomas
Leukemias
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov